Telix Pharmaceuticals shares rise 1.54% premarket after agreeing to resubmit new drug application with FDA.

Telix Pharmaceuticals Limited rose 1.54% in premarket trading, with the company agreeing to resubmit a new drug application for Pixclara to the FDA. This news aligns with the positive movement of the stock, as it indicates progress in the company's drug development pipeline.